Writing · October 13, 2026 · W. Stetson Line

A Guide to the 2026 CDISC US Interchange Presentations

Recurring themes, key takeaways, a summary by topic, upcoming dates, and a directory of all 88 presentations.

The 2026 CDISC Interchange featured 88 presentations. Like many attendees, I was only able to catch a fraction of the sessions I wanted to see in person. To bridge the gap, I used AI to analyze every slide deck, extract the main themes, highlight key takeaways, and create a topic-based directory. If you have access to the archive, this guide will help you quickly locate the presentations most relevant to your team. If you missed the event entirely, it offers a comprehensive overview and a preview of what to expect in the coming year.

The codes in parentheses are the archive's session codes: (4A.2) is session 4, track A, second talk. Codes without a track letter, such as 1.4, are plenary sessions, and codes with several letters, such as 2ABC.1, are joint sessions. Each code links to that presentation. The CDISC program ran in tracks A to C and the TMF program in tracks D and E. I presented one of the talks (5C.2) and summarize it the same way as the rest. The directory of all 88 presentations, grouped by topic, is at the end.

Recurring themes

  1. Machine-readable standards. CDISC's goal is that "By the end of 2030, all CDISC standards are digital, connected, and easily consumable by users and systems" (1.3). SDTMIG v4.0 adds variable groups and root C-codes so that "variables are now semantic entities" (4A.2). The TMF Standard Model V1 will publish its terms in the CDISC CT library, with metadata aligned with USDM where applicable (2DE.2). The current SDS lead noted that "Lots of SDTMIG 4.0 labor could have been avoided with more digitization" (4A.3).
  2. AI drafting with human sign-off. CDISC titled its own 360i Phase 3 method "AI Drafts, a Named Expert Signs" (1.4). Merck's SDTM engine team wrote "Nothing an agent produces is self-approving" (7A.2), and Novartis's PAIR team wrote "AI is the glue, not the foundation" (3C.5). In the TMF track, TransPerfect described keeping the model version, prompts and thresholds under change control (6E.2), and BASE and BeOne treated prompts and model version as versioned settings (4D.2).
  3. Validation alone does not establish correctness. HumanTrue's CTO used the phrase "Valid is not true" to describe USDM files that pass validation and still encode the wrong schedule (6B.2). A protocol-authoring team warned that an agent left unchecked "will produce a plausible, well formed, wrong entity" (5B.2). A Pinnacle 21 consultant asked for "Better Questions, Not More Flags": checks on how the aCRF, SDTM, Define-XML, ADaM and TFLs connect (6A.1).
  4. Traceability from protocol to analysis. 360i followed one endpoint, progression-free survival, from definition to analysis (2ABC.1). BMS described embedding biomedical concept IDs across protocol, eCRF, SDTM and ADaM to catch drift at study build (7C.2). The RWD Lineage talk proposed a Define-XML extension that traces each SDTM data point to its source (4C.2).
  5. Planning for test data. 360i Phase 3 adds a "Synthetic test data facility", with "synthetic data generated for each endpoint, used to test every layer, and shipped with the package" (1.4). The Open Rules team wants "One comprehensive set of test data per bundle" (7B.1), and a TMF AI program advised: "Plan for access and test data as a workstream, not a task" (4D.2). AstraZeneca and ClinChoice set up an unblinded shadow team to catch real-data issues "which don't exist in the dummy data" used for dry runs (4B.3).

Key takeaways

Summary by topic

CDISC strategy and 360i (1.3, 1.4, 2ABC.1 to 2ABC.5)

Conformance rules and CORE (1.4, 7B.1, 6A.1)

SDTM v3.0, SDTMIG v4.0 and non-standard variables (4A.1 to 4A.3, 5A.1)

ADaM (3A.1 to 3A.3, 5A.2, 6A.3)

Digital protocols: USDM, DDF and ICH M11 (5B.1 to 5B.3, 6B.1 to 6B.3, 3B.1 to 3B.3)

Biomedical concepts, eSource, external data and RWD (2ABC.3, 5A.3, 6C.1 to 6C.3, 7C.2, 7C.3, 4C.1 to 4C.3)

Data exchange and submissions (7B.3, 7C.1, 4B.2, 4B.3, 5C.1)

It proposed three checks (schema, a Define-XML cross-check and round-trip integrity) and a 90-day readiness plan. - A talk looking ahead to 2041 placed Dataset-JSON and NDJSON in the submission layer and said "Define-XML stays the metadata" (7C.1). - AstraZeneca and ClinChoice used dummy data in dry runs, and set up an unblinded shadow team to review real data before database lock. They listed the issues it may find as including duplicate records, missing values, outliers and vendor data inconsistent with its transfer specification, "which don't exist in the dummy data" (4B.3). On a pivotal study, they delivered the eCRT package 18 days after receiving database-lock data, compared with 33 days previously (4B.3). - Pfizer reported "88-94% less manual effort" drafting reviewer guides with GenAI. One of its rules: "Missing facts are flagged for the author, never guessed" (5C.1). - Immanant migrated aCRF annotations to MSG v2.0 and assembled Define-XML from a study's existing sources (4B.2).

AI Innovation Challenge and analysis automation (3C.1 to 3C.6, 5C.2, 5C.3, 7A.1 to 7A.3, 7B.2)

TMF (2DE, 3D, 3E, 4D, 4E, 5D, 5E, 6D, 6E, 7DE, 8DE)

Looking ahead

Two reviews are open or about to open: the TMF Standard Model V1 from 19 October, and USDM v4.1 from the end of November. Where to start, by role:

When What Source
October 2026 Open Rules SDTMIG v3.2 to v3.4 and FDA Business Rules packages in production; CORE v1.0 1.4
19 October 2026 TMF Standard Model V1 community review 2DE.1
29 October 2026 Korea CDISC Day, Seoul 8ABC.2
4 to 5 November 2026 CDISC x SCDM Japan Conference, Tokyo 8ABC.2
November 2026 (tentative) RWD Lineage hackathon 4C.2
15 to 18 November 2026 PHUSE EU Connect, Glasgow 8ABC.2
End of November 2026 USDM v4.1 public review opens 1.4
2 December 2026 Webinar: 360i Phase 2 outcomes and the road to Phase 3 1.4
Q4 2026 Open Rules governance group 1.4
End of 2026 Digital DTA internal review 1.4
October 2026 to January 2027 SDTMIG v4.0 public review comment resolution 4A.2
22 January 2027 Japan Academic Workshop (virtual) 8ABC.2
28 to 30 January 2027 CDISC Interchange at PHUSE APAC Connect, Bengaluru 8ABC.2
Q1 2027 Open Rules industry pilot; TMF Standard Model V1 final public review 1.4; 2DE.1
Early 2027 USDM v4.1 publication 1.4
14 to 18 March 2027 PHUSE US Connect, Dallas 8ABC.2
Q1 or Q2 2027 Digital DTA 60-day public review 2ABC.3
Q2 2027, pending comments SDTMIG v4.0 publication 4A.2
April 2027 TMF Standard Model V1 release with implementation guide 2DE.1
26 to 27 May 2027 2027 Europe Interchange, Barcelona 8ABC.2
Second half of 2027 (estimated) ADaM+IG v3.0 public review 3A.1
2027 and beyond Certified rule engines 1.4
18 to 19 October 2027 2027 US Interchange, San Diego 8ABC.2

This year's Denver meeting drew 514 registrants from more than 220 organizations, a record for the US Interchange and 25% more than in 2025 (8ABC.2). CDISC keeps its standards timeline at cdisc.org/standards/timeline.

If you read only five decks, read these:

An open question: is synthetic data good enough?

Several talks touched on a question my next post addresses: when is synthetic or dummy data good enough for the testing it is used for?

My next post, "Is Your Synthetic Data Good Enough?", will address it with the seven assessment axes from my talk (5C.2). If you would judge synthetic study data differently, tell me on LinkedIn.

Directory of presentations by topic

All 88 presentations in the archive, grouped by topic. Titles, presenters and organizations are taken from each deck, with one misspelled name corrected; where a deck prints none, they come from the CDISC program page.

Opening and closing sessions

Code Title Presenters Organizations
1.1 Welcome Jennifer Duff, Karen Roy NA3C; CDISC
1.2 The Rise of Precision Empathy™ Jason Binder Ember
1.3 Industry Pulse… CDISC's 2030 Vision Chris Decker CDISC
1.4 CDISC 360i and the State of the Standards Peter Van Reusel CDISC
8ABC.1 Clinical Trials, Reimagined: What the Next Decade May Look Like Ron Fitzmartin, Jonathan Chainey, Bill Illis, Kristi Bronkan, Stacie L. Daugherty Decision Analytics LLC; Genentech, a member of the Roche Group; Novartis; Kaiser Permanente
8ABC.2 Thank you & Highlights Nicole Harmon CDISC
8DE.3 Closing Jamie Toth BeOne Medicines

CDISC strategy and 360i

Code Title Presenters Organizations
2ABC.1 360i Phase 2: Journey of an Endpoint Julie Smiley CDISC
2ABC.2 360i Phase 2: Define-XML Generation Darren Moreland CDISC
2ABC.3 From Fragmentation to Interoperability: The Digital DTA Transformation Valerie Sheft Merck
2ABC.4 Analysis Concepts: A Standard for Executable Clinical Analysis Edwin van Stein CDISC
2ABC.5 Digital Therapeutic Area User Guides: A Modern Approach to Developing CDISC Standards Bess LeRoy CDISC

Conformance rules and CORE

Code Title Presenters Organizations
6A.1 Seeking Validation: Verified or Truly Vetted? Challenges on the Path to Regulatory Approval Julie Ann Hood Pinnacle 21 by Certara
7B.1 CDISC Open Rules: Progress, Performance, and Foundations for the Future Tomás Sabat Stöfsel Verisian

SDTM, SDTMIG v4.0 and non-standard variables

Code Title Presenters Organizations
4A.1 SDTM 3.0: What's Changed; What's New Michael Wise Edwards LifeSciences
4A.2 What's Coming in SDTMIG v4.0 (and new information since the last interchange) Maria Sekac Merck & Co., Inc.
4A.3 Report from SDS: Future Directions Dave Scocca Rho, Inc.
5A.1 SUPP to NSV: Transforming Data Representation for Improved Reviewer Utility Soumya Rajesh IQVIA

ADaM

Code Title Presenters Organizations
3A.1 ADaM +IG v3.0: Consolidating the Model & Implementation Guide Tatiana Sotingco, Nancy Brucken CDISC ADaM Team
3A.2 Curation of Informative Text as Part of ADaM+IG v3.0 Update Brian Harris CDISC ADaM Team
3A.3 ADaM 3.0 Update Part 3: New Content Sandra Minjoe, Alyssa Wittle ICON plc; Atorus Research
5A.2 Around the Data DOSE-y Doe, How Much Fun Can Your Data Can Be! Inka Leprince, Richann Jean Watson InkaStat Solutions; DataRich Consulting
6A.2 Architectural Divergence Across Three Hemophilia Studies: A Standards-Driven Framework for Rare Disease Multi-Study Programs Prasanna Kakade, Achin Wadhwa Ephicacy Consulting Group
6A.3 From Framework to Practice: Practical ADaM Implementation Jie Yang SGS Pharma Clinical Research

Digital protocols: USDM, DDF and ICH M11

Code Title Presenters Organizations
3B.1 NGSI-LD as a Context Management Layer for CDISC 360i Bo Lora Scientix.ai Inc
3B.2 Semantic Bridges: Linking Study Design to Analytical Concepts Luke Morgan, Bhargav Koduru Medidata
3B.3 AI-Driven Study Orchestration and Implementation: Powered by CDISC Biomedical Concepts Murugesan Vadivel, Chetan Tamballa Saama Technologies
5B.1 Closing the Digital Data Flow Gap Sai Sri Sravya Deevi, Uma Maheswari Adiseshan Zifo RnD Solutions
5B.2 From Study Intent to USDM-Compliant Digital Protocol Achin Wadhwa, Prasanna Kakade Ephicacy Consulting Group
5B.3 From Digital Protocols to Executable Trials Jian Chen EDETEK, Inc.
6B.1 A Guide to Utilizing USDM from Study Concept to Study Execution Chris Damato, Ali Soltani Evinova AG
6B.2 What It Actually Takes Bill Lynch HumanTrue
6B.3 What Breaks First When You Go DDF? Udiksha Jaiswal Sycamore Informatics

Biomedical concepts, eSource, external data and RWD

Code Title Presenters Organizations
4C.1 Bridging the Gap: A Validated Pipeline for Transforming High-Frequency Sensor Data to SDTM Aman Thukral, Sanjay Bhardwaj AbbVie
4C.2 RWD Lineage: A CDISC Standard for Reliable Real-World Data (RWD) Anita Umesh, Tasha Nagamine Data standards consultant (Anita Umesh); Droice Labs (Tasha Nagamine)
4C.3 From Wearables to Regulatory Submissions: Digital Health Technologies in Clinical Research Varun Sethuraman, Venkata Suresh Babu Bondu Hexaware Technologies
5A.3 Transforming Vendor Biomarker Data into CDISC Compliant SDTM Datasets Devi Gohimukkula, Saravanan Kandasamy BeOne Medicines
6C.1 Validating the Site ↔ Vendor ↔ Sponsor Data Workflow Heather Marino Axtria, Inc.
6C.2 Operationalizing CDISC Biomedical Concepts as the Semantic Layer of an eSource Platform Miten Mistry, Abhishek Dabral Paradigm Health
6C.3 Reimagining Clinical Trials with FHIR-to-CDISC Interoperability Prasoon Sangwan, Arka Mazumder Tata Consultancy Services
7C.2 From Intent to Execution: How Biomedical Concepts Quietly Rewired the Safety Data Pipeline Chithra Subramaniam, Rohini Goyal Bristol Myers Squibb
7C.3 Unlocking eSource Potential Jo-Zahn Baxter Axtria

Data exchange and submissions

Code Title Presenters Organizations
4B.2 Interrupting the Conversation: AI-Assisted Clinical Submission Artifacts as a Model for Targeted AI Adoption Carlo Radovsky Immanant
4B.3 Advancing Global Regulatory Submissions through Next Generation Submission (NGS) Carrie Zhang, Asif Karbhari ClinChoice; AstraZeneca
5C.1 From Manual Writing to Intelligent Drafting: Leveraging GenAI to Create Data Reviewer's Guides for Regulatory Submissions Sirisha Davuluri, Valerie Cadorett Pfizer Inc.
7B.3 Dataset-JSON Is Coming: What FDA Adoption Could Mean for Standards, Systems, and Submission Readiness Bill Qubeck Sycamore Informatics
7C.1 Beyond XPT: Reimagining the Clinical Submission for 2041 Raj Chennamaneni, Sudhir Kedare, Stephen Hamburg Jazz Pharmaceuticals

AI Innovation Challenge and analysis automation

Code Title Presenters Organizations
3C.1 Syn2Real: Traceable, AI-generated synthetic SDTM and ADaM for automation testing Thibaud Coroller Novartis
3C.2 Closing the loop: Testing a study build with synthetic data, from USDM to ADaM (Leova) Shirley Collie, Rob Kieser BioInformatiCo
3C.3 Smart ClinSAP: AI Driven Generation of Statistical Analysis Plans Murugesan Vadivel, Chetan Tamballa Saama Technologies
3C.4 SAP-Genie: AI-Driven Generation of Statistical Analysis Plans Raj Chennamaneni, Kumud Kanneganti, Sachin Tiwari, Dilip Nalla, Sudhir Kedare Jazz Pharmaceuticals
3C.5 PAIR: AI TFL Automated Generation Thibaud Coroller, Nicolas Ballarini Novartis
3C.6 TLF GENIX - AI-Driven Tables, Figures, and Listings (TLF) Generation Umamaheswari Adiseshan, Sai Sri Sravya Deevi Zifo RnD Solutions
5C.2 Agentic AI Meets Data Simulation W. Stetson Line Clinventive
5C.3 What happens when analysis and display are independently produced as Analysis Results DataSets (ARDS) and TFLs? Andrew Miskell Eli Lilly and Company
7A.1 From Human-Readable Mappings to Machine-Verifiable SDTM Transformation Specifications with AI-Assisted Authoring Rostislav Markov, Janet Low Amazon Web Services, Inc.; Merck & Co., Inc.
7A.2 Accelerating SDTM Engine Development and Adoption Srini Malipeddi, Proma Debnath Merck & Co., Inc.
7A.3 Governance Powered CDISC Implementation: Driving Standards Reuse at Scale Minda Quiroz, Shyam Ardeshana, Bruce Chambers Alcon; Veramed
7B.2 From Protocol to CSR: Reimagining Clinical Trials with AI and Next-Gen CDISC Models Bhavin Busa Clymb Clinical

TMF

Code Title Presenters Organizations
2DE.1 From Reference Model to Standard Model: How We Got Here Donna Dorozinsky Just in Time GCP
2DE.2 TMF Standard Model V1: Understanding the Architecture Gill Gittens TransPerfect Life Sciences
2DE.3 One Standard, Multiple Subsets Paul Carter Montrium Inc.
3D.1 Same Team, Different Worlds Rob Jones Arithmos Tech
3D.2 Human + AI: Driving TMF Excellence Through Culture, Collaboration, and Connected Systems Harinarayan Gopichandran Sycamore Informatics
3D.3 Transforming TMF Oversight: Applying AI to Address Persistent Site Personnel Record Gaps Niamh Smith, Aaron Grant CSL Behring; Just in Time GCP
3E.1 Elevating the Investigator Site File: Driving Standardization and Data Integrity in Global Clinical Trials Guillaume Gérard Agatha Inc.
3E.2 From Transactional Support to Trusted Partnership: Achieving TMF Excellence Together Jared Brooslin, Seth Pearl Intellia Therapeutics; Phlexglobal
3E.3 From Daily Operations to Audit Spotlight: Standardizing Document Management and Quality Assurance Collaboration Cristina Iannaccone SGS Pharma Clinical Research
4D.1 Smarter TMFs: Solving Today's Challenges While Preparing for an AI-Enabled Future Christina Allen, Angie Gill Daiichi Sankyo, Inc.; Phlexglobal, Inc.
4D.2 From AI Hype to TMF Reality: Early Lessons from Implementing AI Agents Pawel Rucki, Jamie Toth, Nisi Nazim Base life science; BeOne Medicines
4D.3 Redefining TMF Strategy with Agentic AI Jim Horstmann Veeva Systems
4E.1 Leading Change in the Trial Master File Rhonda Nolan Regeneron Pharmaceuticals, Inc.
4E.2 Japanese TMF community update: Recent highlights including TMF RM survey review Yuto Kanda, Mai Nishihara Chugai Pharmaceutical Co., Ltd.; Chugai Clinical Research Center Co., Ltd.
4E.3 TMF Culture: Two TED-Style Provocations Nick Hargaden, Rebecca Halbur Genmab; Moderna
5D.1 The Clinical Study Data Flow Diagram Liz Farrell, Lisa Mulcahy Agios Pharmaceuticals; Mulcahy Consulting, LLC
5D.2 Leverage AI To Accomplish the Impossible: An Inspection Ready TMF Marion Mays, Chad Scribner Jerion Consulting Group; Epista Life Sciences
5D.3 Case Study: The 12-Month TMF Turnaround Suzanne Turner ICE Consulting LLC
5E.1 Your Clinical Systems Are Connected – Your TMF Governance Isn't Olga Radyushkina, Tiffani Nelson Epista; Gilead
5E.2 From Repository to Intelligent Platform: Connected Standards and AI for RWE eTMF Chris Huang, Tom Stonehouse Oracle Health & Life Sciences; Oracle Life Sciences
5E.3 Panel Discussion: End of Study Quality and Archiving Inspection Findings Chris Sigley, Ashley Avery, Liz Farrell, Curran Murphy Arkivum; AbbVie; Agios Pharmaceuticals; Kura Oncology
6D.1 Integrating the Risk Based Principles of ICH E6 R3 to Drive TMF Inspection Steadiness Dawn Niccum inSeption Group
6D.2 The Connected TMF Mindset Christina Mantzioros Montrium
6D.3 Proactive Oversight Means Compliance Confidence Jenn Stamper, Carol Radwanski Just in Time, GCP
6E.1 Leveraging Enterprise AI in TMF Management Brittany Walker USDM Life Sciences
6E.2 Approaches to AI Validation in Regulated Clinical Systems and the eTMF Jay Smith TransPerfect Life Sciences
6E.3 Proving Your TMF Has Not Changed: A Post-Export, Zero-Custody Verification Model Validated in Blinded Multi-Operator Conditions Fernando Telles AuditLog.AI Research Initiative; Cardiovascular Diagnostic Audit & AI Pty Ltd
7DE.2 From Standard to Practice: Bringing TMF SM V1 to Life: Change Management for TMF SM V1 Steph Viscomi Kymera Therapeutics
8DE.2 Moving to a Standard and Beyond Paul Carter Montrium Inc.